$0.39
−8.09%Oct 15, 2026, 12:00 UTC
Humacyte, Inc. reported that the number of hospitals ordering Symvess increased 44% in the third quarter, from 34 at the end of the second quarter to 49 as of September 30, 2026.
Source:Oct 13, 2026, 23:15 UTC
Humacyte, Inc. shares fell 7.88% to $0.36 from the prior session's close.
Source:Oct 6, 2026, 23:01 UTC
Humacyte shares closed at $0.48, down 4.26% from the prior session.
Source:Oct 1, 2026, 23:15 UTC
Humacyte, Inc. (HUMA) shares closed at $0.50, down 2.86% from the prior day's close.
Source:Sep 28, 2026, 12:00 UTC
Humacyte, Inc. appointed life science industry veterans Scott Coward and Paul Kuznik to its Board of Directors.
Source:Sep 18, 2026, 23:00 UTC
Humacyte, Inc. (HUMA) shares closed at $0.59, up 2.23% from the previous close.
Source:Sep 9, 2026, 12:00 UTC
The U.S. Food and Drug Administration authorized Humacyte to extend the expiration dating period for its Symvess product from 18 months to 36 months when stored refrigerated at 2°C to 8°C.
Source:Aug 12, 2026, 00:00 UTC
Humacyte, Inc. reported Q2 2026 revenue of $0.4 million and a net loss of $36.8 million, with diluted EPS of -$0.16.
Aug 5, 2026, 23:01 UTC
Humacyte, Inc. (HUMA) shares rose 2.33% to close at $0.73 in the recent trading session.
Source:Jul 27, 2026, 12:00 UTC
Humacyte announced that the FDA accepted its IND application for a first-in-human clinical study of CTEV for coronary artery bypass grafting.
Source:Jun 11, 2026, 00:56 UTC
Humacyte, Inc. commenced an underwritten public offering of its common stock.